openPR Logo
Press release

CD40 Ligand-Pipeline Review H2 2017

09-26-2017 08:25 PM CET | Health & Medicine

Press release from: ReportsWeb

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG)-CD40 ligand or CD40L is a protein that is primarily expressed on activated T cells and is a member of the TNF superfamily. The CD40-CD40 ligand interaction is crucial to the development of T dependent immune responses. The ligand is expressed on a range of cell types including B cells, granulocytes, macrophages and platelets. T cells expressing CD40L provide signals to B cells that induce proliferation, immunoglobulin class switching, antibody secretion, and rescue from apoptosis at different times during the life of a B cell and also have a role in the development of germinal centres and the survival of memory B cells.

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) pipeline Target constitutes close to 20 molecules. Out of which approximately 18 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 3, 2 and 13 respectively. Similarly, the universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Central Nervous System, Infectious Disease and Hematological Disorders which include indications Breast Cancer, Amyotrophic Lateral Sclerosis, Autoimmune Disorders, Graft Versus Host Disease (GVHD), Hepatitis B, Hepatocellular Carcinoma, Lymphoma, Metastatic Melanoma, B-Cell Chronic Lymphocytic Leukemia, Bladder Cancer, Glioblastoma Multiforme (GBM), Human Immunodeficiency Virus (HIV) Infections (AIDS), Human Papillomavirus Infections, Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), Inflammation, Liver Cancer, Lung Adenocarcinoma, Lung Cancer, Melanoma, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Rheumatoid Arthritis, Sicca Syndrome (Sjogren), Solid Tumor and Systemic Lupus Erythematosus.

The latest report CD40 Ligand-Pipeline Review, H2 2017, outlays comprehensive information on the CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics development with respective active and dormant or discontinued projects.

Request Sample Report@ http://www.reportsweb.com/inquiry&RW00011060477/sample

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG)-Overview 7
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG)-Therapeutics Development 8
Products under Development by Stage of Development 8
Products under Development by Therapy Area 9
Products under Development by Indication 10
Products under Development by Companies 13
Products under Development by Universities/Institutes 16
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG)-Therapeutics Assessment 18
Assessment by Mechanism of Action 18
Assessment by Route of Administration 20
Assessment by Molecule Type 22
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG)-Companies Involved in Therapeutics Development 24
Bristol-Myers Squibb Company 24
eTheRNA Immunotherapies NV 24
Juno Therapeutics Inc 25
MedImmune LLC 25

Inquiry for Buying@ http://www.reportsweb.com/inquiry&RW00011060477/buying

Memgen LLC 26
Multimeric Biotherapeutics Inc 26
Sanofi 26
Tessa Therapeutics Pte Ltd 27
TILT Biotherapeutics Ltd 27
UCB SA 27
XL-protein GmbH 28
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG)-Drug Profiles 29
Cellular Immunotherapy to Activate CD40L and to Target CD19 for B-Cell Malignancies-Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
dapirolizumab pegol-Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
Delta-24-RGDOX-Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Dendritic Cell Therapy + TILT-234-Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34

Find More Information@ http://www.reportsweb.com/cd40-ligand-pipeline-review-h2-2017

List of Figures
Number of Products under Development by Stage of Development, H2 2017 8
Number of Products under Development by Therapy Areas, H2 2017 9
Number of Products under Development by Top 10 Indications, H2 2017 10
Number of Products by Mechanism of Actions, H2 2017 18
Number of Products by Stage and Mechanism of Actions, H2 2017 18
Number of Products by Routes of Administration, H2 2017 20
Number of Products by Stage and Routes of Administration, H2 2017 20
Number of Products by Top 10 Molecule Types, H2 2017 22
Number of Products by Stage and Top 10 Molecule Types, H2 2017 22

About ReportsWeb:
ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.

Contact Us:
Call: +1-646-491-9876
Email: sales@reportsweb.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release CD40 Ligand-Pipeline Review H2 2017 here

News-ID: 741542 • Views:

More Releases from ReportsWeb

North America: Smart Airport Market Overall Study Report 2020-2026| Amadeus IT Group S.A., Cisco, Honeywell, IBM, QinetiQ Group Plc, Sabre Corporation, Siemens ,Rockwell Collins Inc, Thales Group and T Systems International GmbH
North America: Smart Airport Market Overall Study Report 2020-2026| Amadeus IT G …
The "Global North America Smart Airport Market: 2020" Industry Report is a professional and in-depth study on the current state of the North America Smart Airport Market by PMR. The North America Smart Airport market is supposed to demonstrate a considerable growth during the forecast period of 2020 - 2026. The company profiles of all the key players and brands that are dominating the market have been given in this
Marine Biotechnology Market Future Forecast 2018-2026 by Leading Companies such as BASF, Abbott Laboratories, Lonza Group, Nofima, Aker Biomarine, Cyanotech Corporation, New England Biolabs, GlycoMar, Pharmamara, Nutrex Hawaii Incorporated, Marinova, Fmc
Marine Biotechnology Market Future Forecast 2018-2026 by Leading Companies such …
ReportsWeb.com has announced the addition of the “Marine Biotechnology-Global Market Outlook 2017-2026” The report classifies the global Marine Biotechnology Market in a precise manner to offer detailed insights about the aspects responsible for augmenting as well as restraining market growth. According to Publisher, the Global Marine Biotechnology Market is accounted for $3.93 billion in 2017 and is expected to reach $8.74 billion by 2026 growing at a CAGR of 9.3% during
Anti-Counterfeiting Packaging Market Growth Opportunities and Emerging Trends by Analysis of Key Vendors like Alien Technology, 3M Company, Acg Pharmapack, Advanced Track & Trace, AlpVision S.A., Angstrom Technologies, Atlantic Zeiser, TruTag Technologies
Anti-Counterfeiting Packaging Market Growth Opportunities and Emerging Trends by …
ReportsWeb.com has announced the addition of the “Anti-Counterfeiting Packaging-Global Market Outlook 2017-2026” The report classifies the global Anti-Counterfeiting Packaging Market in a precise manner to offer detailed insights about the aspects responsible for augmenting as well as restraining market growth. According to Publisher, the Global Anti-Counterfeiting Packaging Market is accounted for $112.16 billion in 2017 and is expected to reach $427.96 billion by 2026 growing at a CAGR of 16.0% during
Solar Photovoltaic in Italy Market Outlook to 2030 | Company Profiles (Tozzi Holding, Silver Ridge Power, RTR Capital, Mitsubishi Corporation, Etrion Corporation)
Solar Photovoltaic in Italy Market Outlook to 2030 | Company Profiles (Tozzi Hol …
Solar Photovoltaic (PV) in Italy, Market Outlook to 2030, Update 2018-Capacity, Generation, Investment Trends, Regulations and Company Profiles Summary "Solar Photovoltaic (PV) in Italy, Market Outlook to 2030, Update 2018-Capacity, Generation, Investment Trends, Regulations and Company Profiles", is the latest report from Publisher, the industry analysis specialists that offer comprehensive information and understanding of the Solar Photovoltaic (PV) market in Italy. The report provides in depth analysis on global renewable power market and

All 4 Releases


More Releases for CD40

Insights on the CD40 Ligand Market to 2022 | Industry Statistics, Emerging Deman …
The global CD40 Ligand market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). CD154, also known as CD40 ligand or CD40L, is a member of the TNF superfamily of molecules that is largely expressed on activated T cells. It attaches to CD40 (protein) on antigen-presenting cells (APC), resulting in a variety of consequences depending on the kind of target cell.CD40 expression has also been found
CD40 Ligand Market 2022 | Detailed Report
The CD40 Ligand research report provides a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The data thus presented is reliable, comprehensive and the result of extensive research both primary and secondary. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. Moreover, the data underlines the primary and secondary drivers,
Cd40 Ligand Market is Expected to Boom Worldwide by 2027
Global Cd40 Ligand Market report published by the Stratagem Market Insights provides detailed information about Cd40 Ligand Market from various aspects. This report consists of drivers, challenges, and opportunities that help the market grow over the analysis period and recent trends that support market growth. This report consists of regional segmentation with product type and applications. Cd40 Ligand Market Key Vendors: ImmuNext, Inc., Targovax AS, XL-protein GmbH, Biogen, Inc., eTheRNA Immunotherapies NV,
Global CD40 Ligand Market 2018 - Biogen, Inc., ImmuNext, Inc., MedImmune, LLC, T …
Apex Market Reports, recently published a detailed market research study focused on the “CD40 Ligand Market” across the global, regional and country level. The report provides 360° analysis of “CD40 Ligand Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend of CD40 Ligand on
CD40 Ligand Pipeline Insight and Therapeutic Assessment Reviewed in 2017
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - CD40 ligand or CD40L is a protein that is primarily expressed on activated T cells and is a member of the TNF superfamily. “CD40 Ligand Pipeline Review, H2 2017” The CD40-CD40 ligand interaction is crucial to the development of T dependent immune responses. Request For Free
Global Market Report On CD40 Ligand Pipeline Review, H2 2017
"The Report CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG)